A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants

Phase 1 Active not recruiting 32 enrolled Innovent Biologics (Suzhou) Co. Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 1-day treatment period and 12-week follow-up period.

Timeline

Start: 2025-12-31
Primary completion: 2026-06-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IBI3033	Unknown	—	Subcutaneous

Indications

No indication recorded.